1. Jakobsen , JC , Katakam , KK , Schou , A et al . Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis . BMC Psychiatry. 2017 ; 17 : 58 .

2. Bielefeldt , AO , Danborg , PB , Gotzsche , PC . Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers . J R Soc Med 2016 ; 109 : 381 – 392 .

3. Schneider , LS , Nelson , JC , Clary , CM et al . An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression . Am J Psychiatry 2003 ; 160 : 1277 – 1285 .

4. Kasper , S , De Swart , H , Friis Andersen , H . Escitalopram in the treatment of depressed elderly patients . Am J Geriatr Psychiatry 2005 ; 13 : 884 – 891 .

5. Lundbeck . Clinical trial report summary – study 99024, 2005. Available at . Clinical trial report summary – study 99024, 2005. Available at http://www.lundbeck.com/upload/trials/files/pdf/completed/99024_CTRS_final_30Dec2005.pdf

6. Kranzler , HR , Mueller , T , Cornelius , J et al . Sertraline treatment of co-occurring alcohol dependence and major depression . J Clin Psychopharmacol 2006 ; 26 : 13 – 20 .

7. Lundbeck . Clinical trial report summary – study 99003, 2005. Available at . Clinical trial report summary – study 99003, 2005. Available at http://www.lundbeck.com/upload/trials/files/pdf/completed/99003_CTRS_final_30Dec2005.pdf

8. Hypericum Depression Trial Study Group . Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial . JAMA. 2002 ; 287 : 1807 – 1814 .

9. Astrazeneca . ClinicalTrials.gov study results – NCT01020799, 2012. Available at . ClinicalTrials.gov study results – NCT01020799, 2012. Available at https://clinicaltrials.gov/ct2/show/results/NCT01020799

10. Glaxosmithkline . Scientific result summary – PAR 29060.02.001, 2008. Available at . Scientific result summary – PAR 29060.02.001, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1860.pdf

11. Glaxosmithkline . Scientific result summary – PAR 29060.03.003, 2008. Available at . Scientific result summary – PAR 29060.03.003, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1876.pdf

12. Glaxosmithkline . Scientific result summary – PAR 29060.03.001, 2008. Available at . Scientific result summary – PAR 29060.03.001, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/2780.pdf

13. Glaxosmithkline . Scientific result summary – 29060.487, 2005. Available at . Scientific result summary – 29060.487, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2063.pdf

14. Glaxosmithkline . Scientific result summary – 29060.625, 2005. Available at . Scientific result summary – 29060.625, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/1910.pdf

15. Glaxosmithkline . Scientific result summary – WELL AK1A4006, 2005. Available at . Scientific result summary – WELL AK1A4006, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/820.pdf

16. Glaxosmithkline . Scientific result summary – WELL AK1A4007, 2005. Available at . Scientific result summary – WELL AK1A4007, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/821.pdf

17. Glaxosmithkline . Clinical study register. Available at . Clinical study register. Available at https://www.gsk-clinicalstudyregister.com/

18. Sweeting , MJ , Sutton , AJ , Lambert , PC . What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data . Stat Med. 2004 ; 23 : 1351 – 1375 .

19. Friedrich , JO , Adhikari , NK , Beyene , J . Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data . BMC Med Res Methodol 2007 ; 7 : 5 .

20. Pettinati , HM , Oslin , DW , Kampman , KM et al . A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence . Am J Psychiatry 2010 ; 167 : 668 – 675 .

21. Ravindran , AV , Teehan , MD , Bakish , D et al . The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression . Hum Psychopharmacol. 1995 ; 10 : 273 – 281 .

22. De Vries , YA , Roest , AM , Beijers , L , Turner , EH , De Jonge , P . Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: a meta-analysis . Eur Neuropsychopharmacol. 2016 ; 26 : 1752 – 1759 .

23. Ioannidis , JP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced . Arch Intern Med 2009 ; 169 : 1737 – 1739 .

24. Aftonbladet . Dansk studie sågar antidepressiva mediciner (in Swedish), 2017. Available at . Dansk studie sågar antidepressiva mediciner (in Swedish), 2017. Available at http://www.aftonbladet.se/senastenytt/ttnyheter/utrikes/article24393582.ab

25. Sciencenordic . Do antidepressants do more harm than good?, 2017. Available at . Do antidepressants do more harm than good?, 2017. Available at http://sciencenordic.com/do-antidepressants-do-more-harm-good

26. DANISH TV2 . Interview with Janus Christian Jakobsen, 2017. Available at . Interview with Janus Christian Jakobsen, 2017. Available at https://www.youtube.com/watch?v=XRJevSWYE2o

27. Ball , WA , Snavely , DB , Hargreaves , RJ , Szegedi , A , Lines , C , Reines , SA . Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder . Hum Psychopharmacol. 2014 ; 29 : 568 – 577 .

28. Nyth , AL , Gottfries , CG , Lyby , K et al . A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia . Acta Psychiatr Scand 1992 ; 86 : 138 – 145 .

29. Glaxosmithkline . Scientific result summary – 29060.810, 2005. Available at . Scientific result summary – 29060.810, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2204.pdf

30. Mathews , M , Gommoll , C , Chen , D , Nunez , R , Khan , A . Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial . Int Clin Psychopharmacol 2015 ; 30 : 67 – 74 .

31. Forest Laboratories . ClinicalTrials.gov – NCT01473381, 2014. Available at . ClinicalTrials.gov – NCT01473381, 2014. Available at https://clinicaltrials.gov/ct2/show/results/NCT01473381

32. Glaxosmithkline . Scientific result summary – 29060.785, 2005. Available at . Scientific result summary – 29060.785, 2005. Available at https://www.gsk-clinicalstudyregister.com/files2/2202.pdf

33. US Food and Drug Administration, Center for Drug Evaluation and Research . Statistical review – Lexapro NDA 021323, 2001. Available at . Statistical review – Lexapro NDA 021323, 2001. Available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-323.pdf_Lexapro_Statr.pdf

34. Higgins , JPT , Green , S . Cochrane handbook for systematic reviews of interventions version 5.1.0, 16.5.4, 2011. Available at . Cochrane handbook for systematic reviews of interventions version 5.1.0, 16.5.4, 2011. Available at http://handbook-5-1.cochrane.org/chapter_16/16_5_4_how_to_include_multiple_groups_from_one_study.htm

35. Feighner , JP , Overo , K . Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression . J Clin Psychiatry 1999 ; 60 : 824 – 830 .

36. Groenwold , RH , Rovers , MM , Lubsen , J , Van Der Heijden , g . Subgroup effects despite homogeneous heterogeneity test results . BMC Med Res Methodol 2010 ; 10 : 43 .

37. Loo , H , Hale , A , D’haenen , H . Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study . Int Clin Psychopharmacol 2002 ; 17 : 239 – 247 .

38. Lundbeck . Clinical trial report summary – study 99001, 2005. Available at . Clinical trial report summary – study 99001, 2005. Available at http://www.lundbeck.com/upload/trials/files/pdf/completed/99001_CTRS_final_30Dec2005.pdf

39. US Food and Drug Administration, Center for Drug Evaluation and Research . Celexa label, 2012. Available at . Celexa label, 2012. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020822s042,021046s019lbl.pdf

40. Medicines and Healthcare Products Regulatory Agency . Package leaflet – information for the user (Citalopram), 2016. Available at . Package leaflet – information for the user (Citalopram), 2016. Available at http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1466141077922.pdf

41. Ostergaard , SD . Do not blame the SSRIs: blame the Hamilton Depression Rating Scale . Acta Neuropsychiatr. 2017 : 1 – 3 .

42. Wernicke , JF , Dunlop , SR , Dornseif , BE , Zerbe , RL . Fixed-dose fluoxetine therapy for depression . Psychopharmacol Bull. 1987 ; 23 : 164 – 168 .

43. Wernicke , JF , Dunlop , SR , Dornseif , BE , Bosomworth , JC , Humbert , M . Low-dose fluoxetine therapy for depression . Psychopharmacol Bull. 1988 ; 24 : 183 – 188 .

44. Mendels , J , Kiev , A , Fabre , LF . Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia . Depress Anxiety. 1999 ; 9 : 54 – 60 .

45. Glaxosmithkline . Scientific result summary – PAR 29060.02.002, 2008. Available at . Scientific result summary – PAR 29060.02.002, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1861.pdf

46. Glaxosmithkline . Scientific result summary – PAR 29060.02.003, 2008. Available at . Scientific result summary – PAR 29060.02.003, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1862.pdf

47. Glaxosmithkline . Scientific result summary – PAR 29060.02.004, 2008. Available at . Scientific result summary – PAR 29060.02.004, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/2820.pdf

48. Glaxosmithkline . Scientific report summary – PAR 29060.03.002, 2008. Available at . Scientific report summary – PAR 29060.03.002, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1875.pdf

49. Glaxosmithkline . Scientific result summary – PAR 29060.03.004, 2008. Available at . Scientific result summary – PAR 29060.03.004, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1877.pdf

50. Glaxosmithkline . Scientific result summary – PAR 29060.03.005, 2008. Available at . Scientific result summary – PAR 29060.03.005, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1878.pdf

51. US Food and Drug Administration, Center for Drug Evaluation and Research . Paxil NDA 020031 approval letter, statistical review, 1992.

52. US Food and Drug Administration, Center for Drug Evaluation and Research . Celexa NDA 20-822 approval letter, medical review (part 5), 1998. Available at . Celexa NDA 20-822 approval letter, medical review (part 5), 1998. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020822a_medr_P5.pdf

53. Fabre , LF . A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients . J Clin Psychiatry 1992 ; 53 ( Suppl ): 40 – 43 .

54. Glaxosmithkline . Scientific result summary – PAR 29060.03.006, 2008. Available at . Scientific result summary – PAR 29060.03.006, 2008. Available at https://www.gsk-clinicalstudyregister.com/files2/1879.pdf

55. Hieronymus , F , Nilsson , S , Eriksson , E . A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors . Transl Psychiatry. 2016 ; 6 : e834 .

56. Hieronymus , F , Emilsson , JF , Nilsson , S , Eriksson , E . Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression . Mol Psychiatry. 2016 ; 21 : 523 – 530 .